Catalent buys into new antibody tech; Mousera raises $20M;

> Catalent ($CTLT) has inked a deal with Excelimmune to get its hands on some new antibody technology, allowing the company to better manufacture combination therapies. More

> Startup Mousera raised $20 million to advance its ambitions of using Big Data to improve preclinical drug development. Story